MX9802849A - Una composicion antibacteriana para administracion oral. - Google Patents

Una composicion antibacteriana para administracion oral.

Info

Publication number
MX9802849A
MX9802849A MX9802849A MX9802849A MX9802849A MX 9802849 A MX9802849 A MX 9802849A MX 9802849 A MX9802849 A MX 9802849A MX 9802849 A MX9802849 A MX 9802849A MX 9802849 A MX9802849 A MX 9802849A
Authority
MX
Mexico
Prior art keywords
cefditorene
composition
pivoxil
water
oral administration
Prior art date
Application number
MX9802849A
Other languages
English (en)
Inventor
Kenichi Abe
Masato Ota
Hiroyuki Yamaguchi
Chikako Murakami
Toshihiro Kikkoji
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Publication of MX9802849A publication Critical patent/MX9802849A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Ahora se proporciona una composicion antibacteriana nueva para uso en administracion oral, la cual comprende una mezcla de pivoxil de Cefditoren con una sal de caseina soluble en agua. Esta composicion tiene un sabor amargo reducido de pivoxil de Cefditoren y también ha mejorado las propiedades referentes a la velocidad y concentracion de disolucion de pivoxil de Cefditoren en el agua y una relacion de disolucion de pivoxil de Cefditoren en el agua. Esta composicion además puede lograr una excelente capacidad de absorcion del componente de Cefditoren en los tubos digestivos cuando se administra por vía oral. En esta composicion, la relacion (en peso) de pivoxil de Cefditoren a la sal de caseina agregada puede estar de preferencia en una gama de 1:01 a 1:4 . Mediante la adicion de una sal de ácido polifosforico soluble en agua a la composicion, la composicion puede evitar que una relacion de disolucion en el agua del componente de pivoxil de Cefditoren sea disminuida durante el almacenamiento de la composicion bajo condiciones severas.
MX9802849A 1995-10-13 1998-04-13 Una composicion antibacteriana para administracion oral. MX9802849A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26584795 1995-10-13

Publications (1)

Publication Number Publication Date
MX9802849A true MX9802849A (es) 1998-11-30

Family

ID=17422903

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9802849A MX9802849A (es) 1995-10-13 1998-04-13 Una composicion antibacteriana para administracion oral.

Country Status (16)

Country Link
US (1) US5958915A (es)
EP (1) EP0862915B1 (es)
KR (1) KR100311576B1 (es)
CN (1) CN1102046C (es)
AR (1) AR004014A1 (es)
AT (1) ATE214930T1 (es)
BR (1) BR9610836A (es)
CA (1) CA2234426C (es)
DE (1) DE69620220T2 (es)
ES (1) ES2174109T3 (es)
HK (1) HK1016477A1 (es)
HU (1) HU224922B1 (es)
MX (1) MX9802849A (es)
PT (1) PT862915E (es)
TW (1) TW458778B (es)
WO (1) WO1997013516A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1051978E (pt) * 1998-01-07 2012-11-20 Meiji Seika Pharma Co Ltd Composições de cefalosporina amorfa cristalograficamente estável e processo para a sua produção
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
WO2002041887A1 (fr) * 2000-11-21 2002-05-30 Kyorin Pharmaceutical Co., Ltd. Preparations seches de sirop
US7125565B2 (en) 2000-12-01 2006-10-24 Kyowa Hakko Kogyo Co., Ltd. Composition improved in the solubility or oral absorbability
US20030060451A1 (en) * 2001-05-29 2003-03-27 Rajneesh Taneja Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
EP1401402B1 (en) 2001-05-29 2016-09-07 Takeda Pharmaceuticals U.S.A., Inc. Enhancement of oral bioavailability of non-emulsified formulation of cefditoren pivoxil with lecithin
TW200306868A (en) * 2002-05-22 2003-12-01 Shionogi & Co Composition of hardly soluble medicine with improved solubility
AUPS303202A0 (en) * 2002-06-20 2002-07-11 Pacific Biolink Pty Limited Protein based oral lubricant
KR101019769B1 (ko) 2002-10-02 2011-03-04 메이지 세이카 가부시키가이샤 경구 흡수성이 개선된 항균성 약제학적 조성물
ATE539738T1 (de) * 2003-10-08 2012-01-15 Meiji Seika Pharma Co Ltd Nichtkristalline antibakterielle zusammensetzung mit cefditoren-pivoxil
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
EP2401997B1 (en) 2004-11-16 2016-08-24 3M Innovative Properties Company Dental compositions with calcium phosphorus releasing glass
CN101098673B (zh) 2004-11-16 2012-02-29 3M创新有限公司 包括磷酸盐的牙科填料和组合物
EP1811944B1 (en) 2004-11-16 2010-09-08 3M Innovative Properties Company Compositions including a caseinate treated dental filler
CN101115459B (zh) 2004-11-16 2012-03-21 3M创新有限公司 包括含磷表面处理的牙科填料
EP1954253A4 (en) 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
US20080069879A1 (en) * 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
US8790707B2 (en) 2008-12-11 2014-07-29 3M Innovative Properties Company Surface-treated calcium phosphate particles suitable for oral care and dental compositions
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
US20130143857A1 (en) * 2010-07-23 2013-06-06 Lupin Limited Pharmaceutical compositions of cefditoren pivoxil
WO2016114727A1 (en) 2015-01-16 2016-07-21 Öğün Yusuf Toktamiş Cefditoren pivoxil compositions with improved stability and production methods thereof
CN105663058A (zh) * 2016-02-01 2016-06-15 济南康和医药科技有限公司 一种头孢妥仑匹酯纳米粒药物制剂及制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936609A (ja) * 1982-08-26 1984-02-28 Nitto Electric Ind Co Ltd 粘着性貼付製剤
JPS59184122A (ja) * 1983-03-31 1984-10-19 Nitto Electric Ind Co Ltd アクリル系膏体
JPS60102168A (ja) * 1983-11-08 1985-06-06 Tsukishima Shokuhin Kogyo Kk エイコサペンタエン酸強化乳化物及び食品の製造方法
IE58487B1 (en) * 1984-09-07 1993-09-22 Kaisha Maiji Seika New cephalosporin compounds and the production thereof
JPH0678234B2 (ja) * 1988-04-19 1994-10-05 明治製菓株式会社 経口投与用抗菌組成物
JPH0635394B2 (ja) * 1989-02-28 1994-05-11 雪印乳業株式会社 薬物の溶解性および吸収性の改善方法
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
JPH0840907A (ja) * 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd セファロスポリン注射剤

Also Published As

Publication number Publication date
KR100311576B1 (ko) 2001-12-28
DE69620220D1 (de) 2002-05-02
BR9610836A (pt) 1999-07-13
CA2234426C (en) 2003-07-08
CN1102046C (zh) 2003-02-26
PT862915E (pt) 2002-09-30
EP0862915A1 (en) 1998-09-09
AR004014A1 (es) 1998-09-30
EP0862915B1 (en) 2002-03-27
CA2234426A1 (en) 1997-04-17
HUP9900609A3 (en) 2001-04-28
ATE214930T1 (de) 2002-04-15
US5958915A (en) 1999-09-28
ES2174109T3 (es) 2002-11-01
DE69620220T2 (de) 2002-11-28
HU224922B1 (en) 2006-04-28
HUP9900609A2 (hu) 1999-07-28
CN1202110A (zh) 1998-12-16
EP0862915A4 (en) 1998-11-11
TW458778B (en) 2001-10-11
HK1016477A1 (en) 1999-11-05
WO1997013516A1 (fr) 1997-04-17
KR19990064137A (ko) 1999-07-26

Similar Documents

Publication Publication Date Title
MX9802849A (es) Una composicion antibacteriana para administracion oral.
CA2046679A1 (en) Pharmaceutical composition for rapid suspension in water
BG104412A (en) Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
IE872400L (en) Pharmaceutical compositions
CA2265766A1 (en) Rapidly disintegrating pellets
IL123889A0 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
RO116342B1 (ro) Compoziţie farmaceutică lichidă, orală
CA2269807A1 (en) Substituted aminoalkanephosphonic acids
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
MX9504034A (es) Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas.
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
MY109531A (en) Effervescent antacid
BG105436A (en) Pharmaceutical compositions comprising entacapone or nitecapone as well as a cross-linked cellulpse derivative
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
GR3004148T3 (es)
MY119090A (en) Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them
CA2127472A1 (en) New adenosine derivatives, preparation methods and pharmaceutical compositions containing them
EP1285660A4 (en) ZINC SUPPLEMENTARY COMPOSITIONS FOR ORAL ADMINISTRATION
NZ332655A (en) Pharmaceutical compositions containing diclofenac and alkali metal bicarbonates
CA2063273A1 (en) Surfactant compositions and methods
ES8700054A1 (es) Procedimiento de obtencion de germicidas a base de acidos clorhidrico y fosforico.
BG103306A (en) Liquid allendronate compositions
CA2132378A1 (en) Solid, dry, chlorine-free antimicrobial compositions, and method of use
GB2258397A (en) Pharmaceutical compositions containing amethocaine
CA2065889A1 (en) Increasing the choroidal blood flow